Altimmune to Present at Upcoming Conferences
Details on the H.C. Wainwright fireside chat presentation are as follows:
A webcast link to the H.C. Wainwright fireside chat presentation will be accessible on the Events section of the Altimmune website.
Details on the NASH-TAG 2021 presentation by Dr.
|Title:||Dual GLP-1 Agonists in the Treatment of Metabolic
& Liver Dysfunction in NASH
A copy of the presentation materials will be accessible on the Events section of the Altimmune website.
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Investor & Media Contacts:
|Chief Financial Officer||Sr. Dir, Investor Relations|
|Phone: 240-654-1450||Phone : 410-474-8200|
Source: Altimmune, Inc.